CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
News
Netherlands Moves to Cut Mental Health Wait Times for 2026
The Dutch Healthcare Institute prioritizes group therapy and preventive mental health care to reduce long wait times under its 2026–2028 appropriate care agenda.
BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts
CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.
ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
Medline Raises $6.26B in 2025’s Biggest IPO
Medline has raised about $6.26B in an upsized IPO, surpassing CATL’s listing to become 2025’s largest debut.
CMS Reopens National TAVR Coverage Review at Edwards’ Request
CMS has accepted Edwards Lifesciences’ request to reopen the national coverage determination for TAVR, launching a review that could expand access to asymptomatic patients and ease procedural barriers by late 2026.
Genentech Strikes $1.1B Cancer AI Deal With Caris
Genentech has signed a multi-year oncology collaboration with Caris Life Sciences worth up to $1.1B, tapping the techbio’s AI-driven tumor database to discover new solid-tumor targets as year-end dealmaking accelerates.
ICER Backs Wegovy, Zepbound Value in Obesity but Flags Access Crunch
The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more
Zealand, OTR Sign Up to $2.5B Metabolic Drug Deal
Zealand Pharma’s up-to-$2.5B collaboration with OTR Therapeutics highlights a strategic pivot in metabolic drug development.
Yarrow Snags $1.37B TSHR Thyroid Drug From GenSci
Yarrow lands $1.37B China biotech deal, betting on first-in-class TSHR antibody for thyroid disease U.S.-based Yarrow Bioscience has secured its lead asset through a potential $1.37 billion licensing deal with China’s GenSci Pharmaceutical, picking up ex-China rights to a first-in-class antibody targeting autoimmune thyroid disease as it charts a broader expansion beyond its early platform … Read more